Handelsbanken Fonder AB Has $3.56 Million Stake in Medpace Holdings, Inc. $MEDP

Handelsbanken Fonder AB trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,340 shares of the company’s stock after selling 1,360 shares during the period. Handelsbanken Fonder AB’s holdings in Medpace were worth $3,561,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MEDP. NewEdge Advisors LLC lifted its position in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Medpace during the second quarter worth approximately $296,000. Finally, M&T Bank Corp lifted its position in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Glancy Prongay Wolke & Rotter, Faruqi & Faruqi, Schall, Rosen, Pomerantz, and Robbins Geller, issued fresh reminders about the Medpace securities class action and lead-plaintiff deadline, keeping legal overhang front and center for investors. Article title: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class action alleges investor harm and possible violations of federal securities laws, with some notices specifically referencing alleged misstatements and concealed cancellation-rate risks, which could raise uncertainty around the company’s disclosures and future financial exposure. Article title: MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Management Allegedly Concealed Cancellation Rate Risks
• Neutral Sentiment: A separate local business article noted a Cincinnati biopharma firm led by Medpace founder Evan Stein making its commercial debut, but it did not include any direct update on Medpace’s operating outlook or financial results. Article title: Cincinnati biopharma firm helmed by Medpace founder makes commercial debut

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 20.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on MEDP shares. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Robert W. Baird reduced their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Royal Bank Of Canada reduced their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Truist Financial reduced their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Finally, TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $432.80 on Friday. The company’s 50 day simple moving average is $458.92 and its 200 day simple moving average is $519.45. Medpace Holdings, Inc. has a fifty-two week low of $287.17 and a fifty-two week high of $628.92. The firm has a market capitalization of $12.36 billion, a P/E ratio of 27.20, a P/E/G ratio of 2.20 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same period in the prior year, the business posted $3.67 earnings per share. Medpace’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.